ZHUHAI, China, Dec. 18, 2025 — Rezubio, a China-based biotech firm established by former Merck scientists, today declared the completion of a $20 million Series A financing. The funds will be utilized to progress the company’s leading program into Phase 2 clinical development for obesity and diabetes, along with other programs in the IND-enabling stage and early preclinical stage.
The financing was spearheaded by Lapam Capital, with participation from Frees Fund and Riverhead Capital.
“This Series A marks a significant turning point for Rezubio,” stated Yusheng Xiong, PhD, co-founder and CEO of Rezubio. “Membrane anchoring has the potential to transform the design of targeted medications. Our MADD platform enables highly localized pharmacology for cell-surface targets, including GPCRs, while minimizing systemic exposure. Our gut-targeted GPCR agonist has entered clinical trials in Australia and is anticipated to offer crucial proof-of-concept for the platform. Meanwhile, an antagonist targeting a different GPCR for immune and inflammatory diseases will enter Phase 1 clinical development in early 2026.”
A Novel Approach to Tissue-Selective Delivery: Membrane-Anchored Drug Design (MADD)
Rezubio’s MADD platform employs a rationally engineered kinetophore to anchor pharmacophores to the epithelium of target tissues, enabling localized drug activity at the site of action. This approach is designed to achieve:
- Minimal systemic exposure, reducing the risk of off-target and dose-limiting adverse effects
- Enhanced efficacy through enrichment of active compounds around cell-surface target proteins
- Prolonged tissue residence time, supporting less frequent dosing
By addressing the limitations of conventional small-molecule and peptide therapeutics, such as adverse effects and frequent administration, Rezubio aims to improve both the therapeutic index and patient compliance.
CONTACT: Media Contact Muhua He General manager contact@rezubio.com +86-16607569689
